This slide show highlights 2016 FDA approvals of cancer treatments, which to date include therapies for RCC, neuroendocrine tumors, Hodgkin lymphoma, CLL, sarcoma, bladder cancer, lung cancer, and breast cancer.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.